Pittsburgh, United States
Peptilogics is a cutting-edge biotechnology company founded in 2013, focused on developing solutions to cure and prevent medical device-related infections (MDRIs). The company positions itself at the intersection of biotechnology and pharmaceutical innovations, with its headquarters to be determined.
The company's flagship product, PLG0206, is a first-in-class drug that disrupts biofilm — the often impenetrable bacterial matrix causing infections in medical devices. This promising therapeutic solution is currently in a Phase 2/3 registration trial for addressing prosthetic joint infections, with potential applications extending to other surgical needs.
Peptilogics recently secured a significant $78.00M Series B investment on October 1, 2025. This round was led by notable investors such as Founders Fund, Beyond Ventures, Narya, Presight Capital, Thiel Capital, and the AMR Action Fund, underscoring substantial confidence in its market potential and innovative approach.
